The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Challenge, 2012Characterizing Region Specific Splice Isoforms of LRRK2
Objective/Rationale:
LRRK2 is one of the most important genetic risk factors that we know about for Parkinson’s disease: Tens of thousands of people in the US have mutations in this gene... -
Resource: Utilizing DATATOP Biospecimens, 2012Protein S-Nitrosylation as a Potential Biomarker for Parkinson’s Disease
Objective/Rationale:
Oxidative and nitrosatvie stress, related to reactive nitrogen (N) and oxygen (O) species, can cause protein misfolding, aggregation and dysfunction, and thus... -
Dyskinesia Challenge, 2012AVP-923 for Levodopa-induced Dyskinesia in Parkinson's Disease
Objective/Rationale:
Dextromethorphan regulates glutamate and serotonin, brain chemicals that help control movements. In people with Parkinson's disease (PD), brain chemical alterations, coupled with... -
Rapid Response Innovation Awards, 2012Glycosylated Opioid Peptides For the Treatment of Levodopa-Induced Dyskinesias
Objective/Rationale:
Nearly all Parkinson's patients will eventually be treated with levodopa. However, the majority of patients will eventually develop disabling side effects known as levodopa-induced... -
Alpha-synuclein Biology Challenge, 2012Normal Role of Synuclein in Mitochondrial Bioenergetics at the Synapse
Objective/Rationale:
Decreasing levels of a-synuclein (SYN) is a promising therapeutic strategy for PD, but the safety of lowering SYN has not been established. Although the normal functions of SYN are... -
Rapid Response Innovation Awards, 2012Stimulation of Protein Clearance Mechanisms to Improve Clearance of Toxic Accumulations of Alpha-synuclein
Objective/Rationale:
Alpha-synuclein protein accumulation in the brain causes neurotoxicity in Parkinson’s disease (PD). Neural cells have a protein degradation mechanism called the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.